Chengdu Kanghua Biological Products Co (SZSE:300841) Total Current Assets : ¥2,644 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Chengdu Kanghua Biological Products Co Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Chengdu Kanghua Biological Products Co's total current assets for the quarter that ended in Mar. 2024 was ¥2,644 Mil.

Chengdu Kanghua Biological Products Co Total Current Assets Historical Data

The historical data trend for Chengdu Kanghua Biological Products Co's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chengdu Kanghua Biological Products Co Total Current Assets Chart

Chengdu Kanghua Biological Products Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

577.31

1,779.51

1,942.59

2,145.10

2,656.90

Chengdu Kanghua Biological Products Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial															2,175.86	2,209.53	2,292.39	2,656.90	2,644.45

Chengdu Kanghua Biological Products Co Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Chengdu Kanghua Biological Products Co's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	1039.366	+	1426.901	+	173.536	+	17.094
	=	2,657

Chengdu Kanghua Biological Products Co's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	1057.829	+	1378.594	+	189.113	+	18.912
	=	2,644

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Chengdu Kanghua Biological Products Co (SZSE:300841) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Chengdu Kanghua Biological Products Co's Liquidation Value for the quarter that ended in Mar. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1057.829	-	600.648	+	0.75 * 1361.642	+	0.5 * 189.113
=	1,573

Chengdu Kanghua Biological Products Co Total Current Assets Related Terms

Thank you for viewing the detailed overview of Chengdu Kanghua Biological Products Co's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Chengdu Kanghua Biological Products Co (SZSE:300841) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chengdu Kanghua Biological Products Co Ltd (SZSE:300841) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 182, Beijing Road, Chengdu Economic and Technological Development Zone, Sichuan Province, Chengdu, CHN, 610100

Website

https://www.kangh.com

Chengdu Kanghua Biological Products Co Ltd is engaged in research, development, production, sales and technical services of biological products for prevention, and the existing products include Group ACYW135 Meningococcal Polysaccharide Vaccine-Maikexin, Rabies Vaccine (human diploid cell) for Human Use, freeze-dried - HDCV. The company's products include ACYW135 Meningococcal Polysaccharide Vaccine; and Rabies Vaccine.

Executives

Sun Wan Feng	Executives
Hou Wen Li	Directors, executives
Wu Wen Nian	Executives
Chen Huai Gong	Executives
Li Sheng You	Executives
Wang Qing Han	Directors, executives
Li Xiao Wen	Supervisors

Chengdu Kanghua Biological Products Co (SZSE:300841) Headlines

No Headlines